With the continuous advancement of the "Healthy China 2030" strategy, the multi-level guarantee model is becoming a new trend. How to link all walks of life to jointly help has become the focus of attention of the industry. On September 21, Shanghai Pharmaceuticals, China Re Life, Magnesium Health, and BCG jointly held the "Building a Multi-level Medical Security System Summit Forum-and the 2020 China Cancer Specialty Drug Payment Report Release Conference", and 200 industry elites Discuss together the challenges and opportunities of a multi-level medical security system.

　　At the meeting, Li Yongzhong, Executive Director, Vice President of Shanghai Pharmaceuticals and General Manager of Shanghai Pharmaceutical Holdings, attended the meeting and delivered a speech. "In recent years, the country has continued to promote the reform of the medical system centered on the "three-medicine linkage". It has promoted drug price cuts through various forms such as zero-markup for drugs, "4+7" mass purchases, and anti-cancer drug national medical insurance negotiations to reduce patients. Burden. In particular, the establishment of a super purchaser like the Medical Insurance Bureau has had a huge impact on the entire medical and pharmaceutical industries. The medical reform with the payer as the core driving force has strongly promoted industrial reforms and built a sustainable multi-level covering the whole people. The medical security system is the main thread.” According to Li Yongzhong, after 3 years of development, Magnesium Health, which was incubated by Shanghai Pharmaceuticals, has become a leader in the field of innovative medical payment. Through cooperation with pharmaceutical companies, insurance and other industries, A variety of payment solutions have been launched, such as medical installment, drug benefits, commercial insurance, and city customized benefit insurance, to actively help Chinese patients solve payment problems.

　　At present, my country's medical security system still has certain gaps, especially in the field of tumor treatment where the treatment cost is relatively high. The market for cancer specialty drugs is growing rapidly, and cancer patients’ ability to pay is relatively limited. Under the guidance of the establishment of a multi-level medical insurance system, how can we help other payers other than basic medical insurance to better ease the payment pressure and make up for the payment gap, thereby reducing It is important to burden patients and increase the availability of cancer-specific drugs. At the meeting, Meixin Health, together with BCG and China Re Life, jointly released the "China Cancer Specialty Drug Payment Report (2020) Brief Edition". Starting from the scale of China's cancer specialty drug market, it analyzed the current status of cancer specialty drug payment, and Prospects and suggestions on how the multi-level guarantee system supports the payment of special cancer drugs.

　　With the continuous deepening of the medical reform, the top-level building of the multi-level security system has been formed, but the cohesion and coordination of all levels are still poor. Therefore, further optimization measures are still needed to promote the development of the multi-level medical security system, including strengthening basic medical care. The triple protection function of insurance, critical illness insurance and medical assistance will accelerate the improvement of the protection and service capabilities of commercial health insurance, and encourage other payers to actively participate. "As an important part of the social security system, the insurance and pharmaceutical industries have joined hands to actively participate in the implementation of the'Healthy China' strategy and focus on the development of the medical and health industry. This is not only an unshirkable historical mission, but also an inevitable requirement for its own development." Mr. Zhang Xiaodong, CEO of Magnesium Health Said.

　　In the long run, the establishment of a multi-level security system requires the joint efforts of the government, commercial insurance companies, pharmaceutical companies, third-party service companies, associations, and think tanks. This forum also gathered experts in these fields to have a lively discussion on how to create a multi-level payment system. At the meeting, representatives from Shanghai Pharmaceuticals Holdings, China Re Life Insurance, Magnesium Health, Shanghai Chuangqi Health Development Research Institute, BCG, pharmaceutical companies, insurance companies and other companies also jointly proposed the establishment of a long-term communication mechanism to create a cross-industry communication platform "Innovation Alliance of Medical Insurance Industry". The alliance can hold regular exchanges and seminars in the future, and is committed to promoting cross-industry integrated exchanges and helping to build a multi-level medical security system.

　　Li Yongzhong, General Manager of Shanghai Pharmaceutical Holdings, Tian Meipan, General Manager of China Re Life, Lu Yindi, Vice President of China Pharmaceutical Commerce Association, Zhang Xiaodong, CEO of Meixin Health, Liu Bin, General Manager of Shanghai Pharmaceutical Cloud Health, Wu Chun, Managing Director of BCG, Global Partner, Zhou Hong, President of Roche Pharmaceuticals China, Chen Siyuan, General Manager of Bristol-Myers Squibb China and Hong Kong, Yin Min, General Manager of AstraZeneca's Oncology Division, Wu Qingyi, Chief Commercial Officer of BeiGene, and Qian Yun, Head of Market Access, Pfizer 15 guests including Jin Xiaodong, Chief Commercial Officer of Chengjianhua, took part in the establishment ceremony.

　　According to the estimation of the payment report of special cancer drugs, most of the payment of special cancer drugs in my country is currently borne by patients completely at their own expense, followed by the medical insurance fund, while the burden of other levels of protection and innovative payment is relatively low. The report puts forward a number of opinions on the role and role of medical insurance and commercial insurance in the payer, as well as the connection with other multi-level guarantees. It is hoped that it can start from the most representative tumor medicines and take the point and area Build a wider range of multi-level guarantees and offer suggestions. The full text of the report will be officially released in November along with the "China Health Insurance Blue Book" series of the Chinese Academy of Social Sciences.